Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis	Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies	Active, not recruiting	Phase 1 / Phase 2	2026-07-14		NCT06097832

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Immix Biopharma, Inc.	2
Nexcella Inc.	3

18 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Baptist Memorial Hospital	Memphis	United States	1
Barbara Ann Karmanos Cancer Institute	Detroit	United States	44
Boston University Medical Center	Boston	United States	16
City of Hope	Duarte	United States	238
Cleveland Clinic	Cleveland	United States	558
Huntsman Cancer Institute at the University of Utah	Salt Lake City	United States	20
Masonic Cancer Center, University of Minnesota	Minneapolis	United States	15
Memorial Sloan Kettering Comprehensive Cancer Center	New York	United States	1
Stanford University	Stanford	United States	213
Sutter Health Alta Bates	Berkeley	United States	2
Swedish Cancer Institute	Seattle	United States	67
The University of Kansas Cancer Center	Fairway	United States	7
Tufts Medical Center	Boston	United States	238
University of California Davis Medical Center	Sacramento	United States	29
University of California Los Angeles	Los Angeles	United States	87
University of Cincinnati Cancer Center	Cincinnati	United States	9
Washington University Siteman Cancer Center	St Louis	United States	3
Winship Cancer Institute, Emory University	Atlanta	United States	47